A Novel Oral Therapy Discovered to Treat Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)
Insmed has made a significant discovery in the field of medical treatment by introducing Brensocatib, a breakthrough therapy for adult patients suffering from Non-cystic Fibrosis Bronchiectasis (NCFBE), aimed at reducing exacerbations.
Brensocatib is an innovative oral medication that acts as a reversible inhibitor of Dipeptidyl Peptidase 1 (DPP1), designed to address bronchiectasis and various other inflammatory conditions. DPP1 is an enzyme found in neutrophils produced in the bone marrow, capable of activating neutrophil serine proteases (NSPs) like neutrophil elastase. By inhibiting DPP1 and its activation of NSPs, Brensocatib may alleviate the detrimental effects of inflammatory diseases, including bronchiectasis.
NCFBE is a severe and life-threatening chronic pulmonary disorder characterized by the permanent enlargement of the bronchi due to a cycle of infection, inflammation, and lung tissue damage. Symptoms include excessive sputum production, shortness of breath, recurrent respiratory infections that exacerbate the underlying condition, and chronic cough.
In the United States, an estimated 340,000 to 520,000 individuals are affected by NCFBE. Unfortunately, there are currently no approved therapies for this condition in the United States, Europe, or Japan. However, Brensocatib, a pioneering and unique treatment, has received approval for use specifically in bronchiectasis.
Brensocatib earned its breakthrough designation based on positive outcomes obtained from the Phase 2 WILLOW study, a global randomized, double-blind, placebo-controlled trial conducted in adults with NCFBE.
